Hydrochlorothiazide
CAS No.
58-93-5
Reference product
ESIDREX/NOVARTIS
Polymorphic form
Form I
Therapeutic Area
Cardiovascular system
Status
commercial
EU DMF readiness
✓
US DMF readiness
017599
CEP
✓
Other documentation
Japanese DMF
Chinese DMF
Korean DMF
Canadian DMF
Brazilian DMF
💉 Available also
in injectable form
Drug description:
Hydrochlorothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. It has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. It is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.
Mechanism of action:
Hydrochlorothiazide affects the distal renal tubular mechanism of electrolyte reabsorption. Hydrochlorothiazide increases excretion of sodium and chloride in approximately equivalent amounts. Natriuresis may be accompanied by some loss of potassium and bicarbonate.
Products protected by valid patents are not offered for commercial sale in countries where the sale of such products constitutes patent infringement but are offered solely for uses reasonably related to the development and submission of information under a law regulating the manufacture, use or sale of drugs. It is within the buyer’s responsibility and liability to check the patent situation of the product in the imported market(s).